19 citations
,
October 2017 in “European Journal of Pharmaceutics and Biopharmaceutics” The gel made of minoxidil and hydroxypropyl-β-cyclodextrin improves hair growth and is good for long-term use.
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
January 2026 in “International Journal of Dermatology” Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.
1 citations
,
January 1997 in “Journal of Investigative Dermatology” RU58841, an androgen receptor blocker, significantly increased hair density, thickness, and length in monkeys when applied topically daily for several months.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.
21 citations
,
September 2001 in “Graefes Archive for Clinical and Experimental Ophthalmology” Minoxidil may help prevent capsular opacification after cataract surgery.
3 citations
,
November 2018 in “The Journal of Clinical Psychiatry” Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.
July 2023 in “SKIN The Journal of Cutaneous Medicine” Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
July 2025 in “Veterinary Parasitology Regional Studies and Reports” NexGard® and Frontline Combo® are both 100% effective at eliminating lice in dogs.
69 citations
,
October 2013 in “Journal of Clinical Psychopharmacology” Naltrexone did not significantly reduce hair pulling but improved cognitive flexibility.
9 citations
,
April 1970 in “Biochemical pharmacology” Stilbamidine and hydroxystilbamidine inhibit enzyme release from lysosomes and have effects similar to cortisol and chloroquine.
44 citations
,
May 1998 in “PubMed” The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
2 citations
,
February 2004 in “Biopolymers” 4-(4-Phenoxybenzoyl)benzoic acid derivatives can both increase and decrease certain types of reactive oxygen species, and may be relevant to hair loss.
50 citations
,
January 2016 in “The FEBS journal” RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
7 citations
,
August 2006 in “Maturitas” Cimicifuga racemosa extract may help prevent and treat prostate issues by inhibiting 5α-reductase.
7 citations
,
July 2020 in “Pigment cell & melanoma research” RT1640 treatment reverses gray hair and promotes hair growth in mice.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
33 citations
,
October 2016 in “European Journal of Pharmaceutical Sciences” Effervescent formulations may improve minoxidil delivery, increasing effectiveness and reducing applications needed.
35 citations
,
December 1979 in “Naunyn-schmiedebergs Archives of Pharmacology” These drugs raise prostaglandin-like material in dog blood, possibly causing blood vessel widening.
Minoxidil can cause hair growth as a side effect.
18 citations
,
January 2013 in “Evidence-based Complementary and Alternative Medicine” Aconiti Lateralis Preparata Radix helps mouse stem cells grow and turn into bone cells faster than usual methods.
1 citations
,
October 2022 in “JAAD case reports” Low-dose oral minoxidil can cause serious heart complications.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
5 citations
,
January 2021 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil is an effective and safe treatment for hair loss.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
March 2025 in “Journal of Clinical Medicine” Low-dose oral minoxidil effectively treats alopecia but can cause side effects like excess hair growth and fluid retention.
42 citations
,
August 2012 in “Psychoneuroendocrinology” Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.